Treprostinil Palmitil Inhalation Powder + Placebo
Phase 3RecruitingInterest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pulmonary Hypertension
Conditions
Pulmonary Hypertension, Interstitial Lung Disease
Trial Timeline
Apr 1, 2026 → Jan 22, 2031
NCT ID
NCT07234032About Treprostinil Palmitil Inhalation Powder + Placebo
Treprostinil Palmitil Inhalation Powder + Placebo is a phase 3 stage product being developed by Insmed for Pulmonary Hypertension. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07234032. Target conditions include Pulmonary Hypertension, Interstitial Lung Disease.
What happened to similar drugs?
20 of 20 similar drugs in Pulmonary Hypertension were approved
Approved (20) Terminated (1) Active (0)
✅Arformoterol Tartrate Inhalation Solution + Arformoterol Tartrate Inhalation Solution + PlaceboSumitomo PharmaApproved
Hype Score Breakdown
Clinical
17
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07481981 | Phase 3 | Recruiting |
| NCT07234032 | Phase 3 | Recruiting |
| NCT07179380 | Phase 3 | Recruiting |
| NCT05649722 | Phase 2/3 | Active |
| NCT06091579 | Phase 1 | Completed |
Competing Products
20 competing products in Pulmonary Hypertension